Compare VLN & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VLN | STRO |
|---|---|---|
| Founded | 2006 | 2003 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 206.8M | 181.4M |
| IPO Year | 2021 | 2018 |
| Metric | VLN | STRO |
|---|---|---|
| Price | $1.56 | $9.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 14 |
| Target Price | $4.00 | ★ $47.23 |
| AVG Volume (30 Days) | ★ 430.4K | 271.7K |
| Earning Date | 11-11-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $38,419,000.00 |
| Revenue This Year | $11.20 | N/A |
| Revenue Next Year | $18.46 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.10 | $0.72 |
| 52 Week High | $3.71 | $43.85 |
| Indicator | VLN | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 40.10 | 22.90 |
| Support Level | $1.43 | N/A |
| Resistance Level | $1.63 | $16.99 |
| Average True Range (ATR) | 0.09 | 1.23 |
| MACD | -0.02 | -0.15 |
| Stochastic Oscillator | 24.18 | 2.70 |
Valens Semiconductor Ltd is a provider of semiconductor products, pushing the boundaries of connectivity by enabling long-reach, high-speed video, and data transmission for the audio-video and automotive industries. It operates in two segments: Cross Industry Business, which includes solutions for the non-automotive verticals, including audio-video, industrial, machine vision and medical markets, that deliver superior, plug-and-play convergence and distribution of different interfaces, through a single long-distance category cable; and Automotive segment products enable safe and resilient high-speed in-vehicle connectivity for car architectures, realizing the vision of connected and autonomous cars. The company's geographical revenue is derived from Hungary.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.